Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc.

LFCRยทNASDAQ

$5.67

+1.5%
HealthcareDrug Manufacturers - Specialty & Generic

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

At a Glance

Live Snapshot
Market Cap$212.68M
EPS-1.2700
P/E Ratio-4.46
Earnings Date07/31/2026
3Y+16.0%
5Y-78.0%
10Y-76.0%
3Y-67.0%
5Y+1.0%
10Y+233.0%
3Y-99.0%
5Y-99.0%
10Y-101.0%
Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc. Profit Bridge

LFCR ยท NASDAQ
Revenue128.87M
Cost of Goods Sold (88.57M)
Gross Profit40.30M
Operating Expenses (57.54M)
Operating Income-17.25M
Interest Expense (21.84M)
Other Income/Expense-21.43M
Pretax Income-38.67M
Income Tax (43.00K)
Net Income-38.72M
Net Income
-38.72M

Profitability Analysis

Gross Margin

31.3%

Moderate margins typical of competitive industries. Monitor for pricing pressure or rising costs.

Operating Margin

-13.4%

Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.

Net Profit Margin

-30.0%

Net losses indicate the company is burning cash. Sustainability depends on path to profitability.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

Lifecore Biomedical, Inc. Income Statement

LFCR โ€ข NASDAQ

Lifecore Biomedical, Inc. Income StatementMay 2025May 2024May 2023May 2022May 2021May 2020May 2019May 2018May 2017May 2016May 2015May 2014May 2013May 2012May 2011May 2010May 2009May 2008May 2007May 2006
REVENUE
128.9M
128.3M
103.3M
111.3M
100.9M
590.4M
557.6M
524.2M
532.3M
541.1M
539.3M
476.8M
441.7M
317.6M
276.7M
238.2M
235.9M
238.5M
210.5M
232M
GROSS PROFIT
(88.6M)
(86.4M)
(75.3M)
(72.2M)
(61.9M)
(515.4M)
(476.6M)
(445.9M)
(449.1M)
(470.1M)
(473.9M)
(414.2M)
(378.9M)
(265.4M)
(230M)
(204.5M)
(201.7M)
(200.3M)
(178.1M)
(191.9M)
40.3M
41.9M
28M
39.1M
38.9M
75M
81M
78.3M
83.2M
71M
65.4M
62.6M
62.8M
52.1M
46.7M
33.8M
34.3M
38.2M
32.4M
40M
OPERATING INCOME
(57.5M)
(50.7M)
(49.8M)
(50.9M)
(47.8M)
(83.3M)
(75.5M)
(64.8M)
(67.7M)
(56.7M)
(46.9M)
(42.4M)
(37.9M)
(36.1M)
(33.9M)
(22.1M)
(21.7M)
(23.1M)
(2M)
(31M)
(44M)
(40.5M)
(39M)
(34.7M)
(27.7M)
(72.2M)
(64.1M)
(52M)
(58.2M)
(49.5M)
(40M)
(35.2M)
(32.5M)
(26.5M)
(24.6M)
(17.7M)
(18M)
(19.8M)
(21.6M)
(28M)
(8.3M)
(8.6M)
(8.7M)
(7.8M)
(6.7M)
(11.1M)
(11.5M)
(12.8M)
(9.5M)
(7.2M)
(7M)
(7.2M)
(9.3M)
(9.6M)
(9.3M)
(4.4M)
(3.7M)
(3.3M)
(3.1M)
(3M)
-17.2M
-8.8M
-21.8M
-11.8M
-8.8M
-8.3M
-8M
11.8M
15.5M
-19.8M
18.5M
20.2M
24.9M
14.6M
8M
11.7M
12.6M
15.2M
30.4M
9M
PRE-TAX INCOME
(21.8M)
(18.1M)
(17.6M)
(15.6M)
(8.9M)
(4.6M)
(5.2M)
(2M)
(1.8M)
(2M)
(1.8M)
(1.7M)
(2M)
(929K)
(820K)
(88K)
(8K)
(0.0)
(0.0)
(0.0)
-21.8M
-18.1M
-17.6M
-15.5M
-8.9M
-4.6M
-5.1M
-1.7M
-1.8M
-1.9M
-1.5M
-1.4M
-1.8M
-749K
-390K
746K
1.3M
0.0
0.0
0.0
(5.2M)
(1.7M)
(2.1M)
(8.4M)
(13.4M)
(0.0)
(0.0)
(0.0)
-333K
(0.0)
(0.0)
(0.0)
(8.1M)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-22.7M
(0.0)
-21.4M
18.4M
-42.1M
-8.9M
-21M
-4.8M
-1.8M
2.8M
-493K
934K
3M
9.7M
7.4M
5.7M
410K
746K
743K
2.2M
1.7M
-24K
-38.7M
9.5M
-63.9M
-20.7M
-29.8M
-51.3M
3.6M
16.4M
15M
-18.9M
21.5M
29.9M
32.3M
20.3M
8.4M
8.7M
13.3M
16.9M
31.6M
9M
NET INCOME
(43K)
(183K)
(308K)
-5.2M
-6.4M
-13.1M
(1.5M)
-9.4M
(4.3M)
-7.4M
(7.7M)
(10.6M)
(9.5M)
(7.2M)
(4.2M)
(4.3M)
(5.6M)
(3.4M)
(2.5M)
(396K)
-38.7M
12M
-99.6M
-116.7M
-32.3M
-38.2M
2.1M
24.8M
10.6M
-11.6M
13.5M
19.1M
22.6M
12.7M
3.9M
4M
7.7M
13.5M
29.2M
8.7M

SEC Filings

LFCR - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
10-Q

10-Q 2026 Q1

Q1

May 06, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 06, 2026
May 06, 2026
2026
DEF 14A

DEF 14A 2026

N/A

April 24, 2026
April 24, 2026
2026
8-K

8-K 2026

N/A

March 16, 2026
March 16, 2026
2026
8-K

8-K 2026

N/A

March 05, 2026
March 05, 2026
2026
8-K

8-K 2026

N/A

January 16, 2026
January 14, 2026
2026
8-K

8-K 2025

N/A

November 17, 2025
November 17, 2025
2025
10-Q

10-Q 2025 Q3

Q3

November 06, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

November 06, 2025
November 06, 2025
2025
8-K

8-K 2025

N/A

October 31, 2025
October 29, 2025
2025
Showing 1 to 10 of 456 filings